Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
13. Oktober 2020 07:05 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Oct. 13, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
25. September 2020 07:05 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...